Dyer Timothy Mark, CEO, reported a transaction classified as grant at Addex Therapeutics Ltd. involving 16413787.000000 shares for an estimated $0.00. Reported holdings after the transaction were 16848979.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.
Form 4 relationship flags and nearby filing context
CHIEF EXECUTIVE OFFICER
Represents 16,413,787 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 9,405,754 were acquired on October 26, 2022 under the deferred st…
On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unc…
The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026.
0 other filings
0 recent txs